Contributions
Abstract: P344
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: There is an unmet need for markers predicting future disability in Multiple Sclerosis (MS) patients.
Objectives: The aim of this study was to investigate whether early alterations in evoked potentials (EP) can serve as a prognostic factor in a homogenous relapsing-remitting (RR) patient cohort with long-term follow-up.
Methods: We retrospectively selected 72 RRMS patients with a neurological follow-up ranging from 5 to 15 years, in whom multimodal EPs were performed at diagnosis. A conventional ordinal score was used to quantify the observed abnormalities.
Results: The extent of change in the composite EP score well correlated to the Expanded Disability Status Scale (EDSS) at ten years (Y10) after onset (R = 0.66, p < 0.0001) and beyond that time point, up to 15 years (Y11-15) of follow-up (R = 0.8, p < 0.0001). Analysis of the predictive value of the EP score showed an increased risk of disability progression at Y10 and Y11-15 of 53.6% (p = 0.0009) and 70.8% (p < 0.0001) respectively. Conversely, the risk of disability progression at Y10 and Y11-15 associated with a lower EP score was reduced to 15.4% and 18.9% respectively. These data were confirmed by the significant worsening of the EDSS scores at 10 years of follow-up and beyond, according to the number of pathological EPs.
Conclusions: Our data support the good predictive value for long-term disability progression of multimodal EPs performed early after disease onset in RRMS patients.
Disclosure:
F. London has received travel grants from Biogen.
S. El Sankari has received travel grants from Biogen, Bayer Schering, Sanofi Aventis, Genzyme, Merck, Teva and Novartis Pharma. Her institution has received honoraria for consultancy from Biogen Idec and Merck.
V. van Pesch has received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution has received honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering.
Abstract: P344
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: There is an unmet need for markers predicting future disability in Multiple Sclerosis (MS) patients.
Objectives: The aim of this study was to investigate whether early alterations in evoked potentials (EP) can serve as a prognostic factor in a homogenous relapsing-remitting (RR) patient cohort with long-term follow-up.
Methods: We retrospectively selected 72 RRMS patients with a neurological follow-up ranging from 5 to 15 years, in whom multimodal EPs were performed at diagnosis. A conventional ordinal score was used to quantify the observed abnormalities.
Results: The extent of change in the composite EP score well correlated to the Expanded Disability Status Scale (EDSS) at ten years (Y10) after onset (R = 0.66, p < 0.0001) and beyond that time point, up to 15 years (Y11-15) of follow-up (R = 0.8, p < 0.0001). Analysis of the predictive value of the EP score showed an increased risk of disability progression at Y10 and Y11-15 of 53.6% (p = 0.0009) and 70.8% (p < 0.0001) respectively. Conversely, the risk of disability progression at Y10 and Y11-15 associated with a lower EP score was reduced to 15.4% and 18.9% respectively. These data were confirmed by the significant worsening of the EDSS scores at 10 years of follow-up and beyond, according to the number of pathological EPs.
Conclusions: Our data support the good predictive value for long-term disability progression of multimodal EPs performed early after disease onset in RRMS patients.
Disclosure:
F. London has received travel grants from Biogen.
S. El Sankari has received travel grants from Biogen, Bayer Schering, Sanofi Aventis, Genzyme, Merck, Teva and Novartis Pharma. Her institution has received honoraria for consultancy from Biogen Idec and Merck.
V. van Pesch has received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution has received honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering.